title: Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome. Influence of gastrinoma growth and long-term omeprazole treatment.
abstract: Evolution of gastrinoma tumoral mass, fasting serum gastrin concentrations, and gastric endocrine cells has been analyzed in 21 patients with the Zollinger-Ellison syndrome committed to long-term omeprazole treatment (up to 7.75 years, median 37 months). Gastrinoma growth was seen in eight patients. Significant increase in serum gastrin was only observed in the group of patients with gastrinoma growth. Fundic argyrophil cell densities were correlated with serum gastrin (r' = 0.68, P = 0.002). Argyrophil and antral gastrin cell densities significantly increased during the survey, but increases were greater in the group with gastrinoma growth (respectively, +136% and +131%) than in the other group (respectively, +34% and +43%). Progression in the degree of argyrophil cell hyperplasia, noted qualitatively, was observed in 11 patients. Fundic carcinoids developed in three of these 11 patients, all three having multiple endocrine neoplasia type 1 (MEN 1). Positive linear individual correlations (r > or = 0.85) between argyrophil cell densities and corresponding durations of omeprazole treatment were found in nine of the 10 patients studied at least three times and who had a clear-cut increase in those cell densities. Thus, increase in serum gastrin and fundic argyrophil cell densities appeared closely associated with gastrinoma growth; however, duration of drug-induced hypochlorhydria may also affect cell proliferation.
authors.affiliation: Department of Gastroenterology, Hôpital Bichat-Claude Bernard, Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Cadiot
authors.forename: T
authors.initials: T
authors.lastname: Lehy
authors.forename: P
authors.initials: P
authors.lastname: Ruszniewski
authors.forename: S
authors.initials: S
authors.lastname: Bonfils
authors.forename: M
authors.initials: M
authors.lastname: Mignon
mesh_terms: D001078:APUD Cells / Q000187:drug effects* / Q000473:pathology; D000328:Adult; D000368:Aged; D016009:Chi-Square Distribution; D002908:Chronic Disease; D005260:Female; D015408:Gastrinoma / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D005755:Gastrins / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009377:Multiple Endocrine Neoplasia / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D009853:Omeprazole / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D011446:Prospective Studies; D013270:Stomach / Q000187:drug effects* / Q000473:pathology; D013997:Time Factors; D015043:Zollinger-Ellison Syndrome / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology
chemical_list: D005755:Gastrins; D009853:Omeprazole